AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00723606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular haloperidol
Description: The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
Study NCT03052582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk type
Study NCT00826267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: lapatinib tablets 1500 mg daily
Study NCT00826267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
Study NCT00826267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
Study NCT02623803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT02623803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo D5W
Study NCT05508529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chaga Mushroom
Description: Effect of chaga on immune/mood support
Study NCT05508529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Algae Extract
Description: Effect of algae extract on immune/mood support
Study NCT05508529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black Cumin Seed Oil
Description: Effect of black cumin seed oil on immune/mood support
Study NCT05508529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black Cumin Seed Oil + Astaxanthin
Description: Effect of Black Cumin Seed Oil + Astaxanthin blend on immune/mood support
Study NCT05508529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black Cumin Seed Oil + Omega 3
Description: Effect of Black Cumin Seed Oil + Omega3 blend on immune/mood support
Study NCT05508529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT00365599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate (Tamoxifen)
Description: Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
Study NCT02215590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Re-Step
Description: Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week.
Study NCT04428866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Continuous Glucose Monitoring
Description: A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed during visit 1 in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
Study NCT04428866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: activity monitor
Description: The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days to assess activity, concurrent with CGM sensor wear.
Study NCT04428866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mixed meal tolerance test
Description: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
Study NCT04428866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glucagon Sensitivity Testing
Description: After baseline blood sampling, glucagon will be administered by injection, and blood samples will be collected for analysis of glucose and hormone responses. This will allow us to assess whether sensitivity to glucagon is altered in PBH.
Study NCT04428866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hypoglycemic Hyperinsulinemic Clamp
Description: This test will assess hormonal responses to hypoglycemia. Participants will arrive after an overnight fast. After baseline blood sampling, an infusion of insulin and glucose will be started, and infusions will be adjusted to allow glucose levels to drop very gradually. Blood samples will be collected for measurement of hormonal responses to lowering of glucose. This test will allow us to determine whether secretion of hormones which counteract hypoglycemia (counterregulatory hormones) is reduced in patients with PBH as compared with other groups.
Study NCT04428866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: analysis of fecal microbiome
Description: Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
Study NCT04073095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (Group E)
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.
Study NCT04073095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified-thoracolumbar interfascial plane block (Group T)
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.
Study NCT01430585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04691502
Description: PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
Study NCT01430585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04691502 in combination with Letrozole
Description: PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
Study NCT01430585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
Study NCT02496780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: novolog insulin
Description: 3x daily rapid-acting insulin
Study NCT02496780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levemir insulin
Description: basal insulin once a day
Study NCT02496780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once or 3x daily
Study NCT02244333 — intervention group
Intervention type: DRUG
Intervention: ALNA®
Study NCT01097837 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: This is an observational study conducted by anonymous survey. There is no intervention.
Study NCT04528446 — intervention group
Intervention type: RADIATION
Intervention: Dual-energy X-ray absorptiometry
Description: DXA whole body, hip, spine, and radius at baseline, and 12-month visit.
Study NCT04528446 — intervention group
Intervention type: RADIATION
Intervention: High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)
Description: HR-pQCT of the radius and tibia at baseline, and 12-month visit.
Study NCT04528446 — intervention group
Intervention type: OTHER
Intervention: Blood draw and Urine collection
Description: The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.
Study NCT04528446 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
Study NCT04388943 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Physiological Measurements Patient reported questionnaire Blood sampling
Study NCT02756793 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
Study NCT02756793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Treatment
Description: May include:~* Continue with current systemic agent(s)~* Observation~* Switch to next-line treatment~Palliative radiotherapy is allowed in this arm.
Study NCT06357988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06357988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04430062 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical procedures performed under general anesthesia
Description: Surgical procedures performed under general anesthesia in patients with perioperative SARS-CoV-2 infection
Study NCT06357988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT06357988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo nuclear study
Study NCT06357988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT02983006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DS-8273a
Description: * Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~* Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)
Study NCT02983006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 5 mg/kg IV Q 3 weeks
Study NCT04593030 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dispensing claim is used as the reference
Study NCT03816423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: Participants randomized to the intervention group, will wacth a pre-appointment video, followed by a routine prenatal care visit.
Study NCT04593030 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Apixaban dispensing claim is used as the exposure
Study NCT01307566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure CPAP
Description: CPAP treatment
Study NCT03807427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: READY-Nepal
Description: Regulating Emotions through Adapted Dialectical behavior skills for Youth in Nepal (READY-Nepal) is a brief (10-session), emotion-focused intervention targeting prevention and reduction of trans diagnostic problems related to emotion regulation. The culturally adapted program is divided into 5 modules, and includes both didactic and experiential instruction in skills related to mindfulness, stress tolerance, emotional awareness and regulation, validation of self and others, and mastery of interpersonal relationships.
Study NCT03518008 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: verofilcon A contact lenses
Description: Investigational daily disposable soft contact lenses
Study NCT04488328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks
Description: patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)
Study NCT03892720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03892720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03892720 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT01110421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
Study NCT01110421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime
Description: Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
Study NCT01110421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
Study NCT01110421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
Study NCT01110421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium
Description: Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
Study NCT03389646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CERAMENT G V
Description: During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM\|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM\|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM\|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU).
Study NCT02252627 — intervention group
Intervention type: DRUG
Intervention: Administration of phenylephrine
Description: Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
Study NCT02252627 — intervention group
Intervention type: OTHER
Intervention: Measurement of stroke volume
Description: The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
Study NCT02252627 — intervention group
Intervention type: OTHER
Intervention: Contrast enhanced ultrasound scan
Description: Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
Study NCT02252627 — intervention group
Intervention type: DRUG
Intervention: Administration of ephedrine
Description: Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
Study NCT01252290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza™
Description: 4 capsules daily for 6 months
Study NCT03384251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive sex education
Description: A comprehensive sex education program to be delivered in approximately six (6) sessions comprising of an introductory lesson on susceptibility and severity of teenage pregnancy, personal and community values, female reproductive system, contraception and decision-making skills.
Study NCT00722917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-379
Description: TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
Study NCT00722917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-379
Description: TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
Study NCT00722917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-379
Description: TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
Study NCT00722917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
Study NCT00722917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
Study NCT02310672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: All patients take open-label macitentan 10mg o.d.
Study NCT04060329 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: coopeRATE Prompt
Description: The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
Study NCT04060329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coopeRATE Prompt
Description: The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
Study NCT00086580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluCAM [Fludara + Campath]
Description: Phase A: Escalating Doses of alemtuzumab (Campath) Alone~Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.~Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.~Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.~Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.~Phase B: FluCAM~Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m\^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity.
Study NCT00086580 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate
Description: Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m\^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
Study NCT04164147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior Cruciate Ligament sacrificing or retaining implant
Study NCT04164147 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT scan
Description: CT scans of the affected knee joint before and after the surgical procedure
Study NCT04164147 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biomechanics
Description: Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively